Mode
Text Size
Log in / Sign up

Genomic analysis shows clonal Campylobacter persistence and gentamicin resistance in two CVID patients.

Genomic analysis shows clonal Campylobacter persistence and gentamicin resistance in two CVID patien…
Photo by National Institute of Allergy and Infectious Diseases / Unsplash
Key Takeaway
Note clonal persistence and gentamicin resistance associations in recurrent C. coli bacteremia within CVID patients.

This retrospective analysis examined antimicrobial use and genomic characteristics of Campylobacter isolates in two patients with common variable immunodeficiency experiencing recurrent bacteremia. The study followed these individuals for 6 to 10 years to assess strain persistence and resistance development. No comparator group was included in this case series design.

For patient #1, 18 C. coli isolates were identified between 2022 and 2024, originating from the same clonal complex and linked to a chicken source. Additionally, 17 C. jejuni isolates were found in two distinct clusters occurring in 2014 and 2022 to 2024. Analysis of resistance markers detected an A1387G 16S rRNA mutation in 4 C. coli isolates from 2022 to 2023, which was associated with gentamicin resistance. One isolate demonstrated resistance to ertapenem due to a PorA protein duplication.

Patient #2 yielded 10 C. coli isolates between 2019 and 2024, all belonging to the same clonal complex of porcine origin. Three isolates from 2023 contained an A1464G 16S rRNA mutation associated with gentamicin resistance. The retrospective analysis highlighted an association between antimicrobial selection pressure and the emergence of these resistance markers, suggesting in vivo selection.

No adverse events, serious adverse events, discontinuations, or specific tolerability data were reported for the antimicrobial regimens used. Key limitations include the very small sample size of two patients and the inherent constraints of an observational design. The study suggests an association between drug use and resistance emergence but does not establish causation. Generalizability to broader populations remains uncertain based on this limited evidence.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
Because few studies have focused on recurrent Campylobacter bacteremia, we investigated two clinical cases of patients with common variable immunodeficiency and repeated Campylobacter bacteremia over a period of 6–10 years. We analyzed and compared genomes from isolates obtained from both patients during follow-up. For patient #1, 18 isolates of Campylobacter coli and 17 isolates of Campylobacter jejuni were obtained from 2014 to 2024. For patient #2, 10 isolates of C. coli were obtained from 2019 to 2024. Next-generation sequencing was used to identify species, characterize antimicrobial resistance, perform multilocus sequence typing, and analyze core-genome single-nucleotide polymorphisms, as well as to uncover potential sources of contamination. For patient #1, all 18 C. coli isolates obtained from 2022 to 2024 were from the same clonal complex and source of contamination (chicken) and exhibited high levels of genomic resemblance based on core-genome single-nucleotide polymorphism analysis. Each C. coli isolate probably originated from the same initial strain. However, two clusters of C. jejuni were identified: one consisting of isolates from 2014 and the other consisting of the remaining isolates from 2022 to 2024. A 16S rRNA mutation in position A1387G was present in four C. coli isolates from 2022 and 2023, and this was associated with gentamicin resistance. One C. coli isolate was also resistant to ertapenem and exhibited an amino acid duplication within the PorA protein sequence. For patient #2, each C. coli isolate was from the same clonal complex, which was of porcine origin. Similar to patient #1, three of the isolates from 2023 had an A1464G 16S rRNA mutation and were gentamicin resistant. Retrospective analyses of antimicrobial use for both patients highlighted an association between antimicrobial selection pressure and the emergence of resistance markers, suggesting in vivo selection.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.